CELON PHARMA

Celon Pharma Files for Approval of Phase II Trial of CPL’280, a Second Generation GPR40 Agonist, in Type 2 Diabetes

Retrieved on: 
Tuesday, June 22, 2021
Health, Diabetes, Disability, Organ systems, Clinical medicine, Anti-diabetic drugs

KIELPIN, Poland, June 22, 2021 (GLOBE NEWSWIRE) -- Celon Pharma today announced filing for approval to start a Phase II clinical study of CPL280, its second generation GPR40 agonist in type 2 diabetes.

Key Points: 
  • KIELPIN, Poland, June 22, 2021 (GLOBE NEWSWIRE) -- Celon Pharma today announced filing for approval to start a Phase II clinical study of CPL280, its second generation GPR40 agonist in type 2 diabetes.
  • This double-blind, randomized, placebo-controlled, multiple dose Phase II study will evaluate the ability of orally administered CPL280 to control blood glucose in patients with diagnosed type 2 diabetes.
  • Celon Pharma expects to dose the first patient in Q4 2021 and top-line results are anticipated in 1H 2022.
  • The molecule, which is structurally different from the first generation agonists, is free from known risk factors associated with liver injury, i.e.

Celon Pharma Hosting a Virtual Capital Markets Day on Wednesday, April 21st

Retrieved on: 
Monday, April 19, 2021

From 2006 to 2014 he held the position of assistant in the Clinic of Adult Psychiatry of the Medical University of \xc5\x81\xc3\xb3d\xc5\xba, Poland.

Key Points: 
  • From 2006 to 2014 he held the position of assistant in the Clinic of Adult Psychiatry of the Medical University of \xc5\x81\xc3\xb3d\xc5\xba, Poland.
  • He is also a member of the Polish Psychiatrists\xe2\x80\x99 Association and a member of International Society for Sports Psychiatry.
  • It has been listed on the Warsaw Stock Exchange since 2016. www.celonpharma.com\nThis press release (\xe2\x80\x9cPress release\xe2\x80\x9d) has been prepared by Celon Pharma S.A. (the \xe2\x80\x9cCompany\xe2\x80\x9d).
  • Persons into whose possession this Press release comes should observe all such restrictions.\nObtain more information by contacting:\n"

Celon Pharma Announces CPL’280, Second Generation Oral GPR40 Agonist, Meets Primary Endpoint in Phase 1 Trial

Retrieved on: 
Thursday, April 1, 2021
Organ systems, Branches of biology, Anatomy, Diabetes, Diabetic neuropathy, Peripheral neuropathy

KIELPIN, Poland, April 01, 2021 (GLOBE NEWSWIRE) -- Celon Pharma S.A. today announced the successful completion of a Phase 1 trial of its second generation GPR40 agonist, CPL280.

Key Points: 
  • KIELPIN, Poland, April 01, 2021 (GLOBE NEWSWIRE) -- Celon Pharma S.A. today announced the successful completion of a Phase 1 trial of its second generation GPR40 agonist, CPL280.
  • No adverse events associated with administration of CPL280 were observed, the primary endpoint of the trial.
  • CPL280 is structurally different from first generation molecules and is designed to improve on the liver toxicity signal identified in earlier programs.
  • It is also the first GPR40 agonist which demonstrated efficacy in diabetic neuropathy animal models after oral administration.

Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor

Retrieved on: 
Wednesday, February 10, 2021
Celon, Pharma

KIELPIN, Poland, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Celon Pharma S.A. today announced the successful completion of its Phase 1A trial of its JAK/ROCK kinases dual inhibitor, CPL116.

Key Points: 
  • KIELPIN, Poland, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Celon Pharma S.A. today announced the successful completion of its Phase 1A trial of its JAK/ROCK kinases dual inhibitor, CPL116.
  • No adverse events associated with administration of the investigational drug were observed, and the trial met its primary endpoint.
  • Celon Pharma is an integrated biopharmaceutical company which designs, develops, manufactures and distributes pharmaceutical products.
  • It has been listed on the Warsaw Stock Exchange since 2016. www.celonpharma.com
    This press release (Press release) has been prepared by Celon Pharma S.A. (the Company).

Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression

Retrieved on: 
Friday, January 8, 2021
Psychiatric diagnosis, Psychoactive drugs, Mood disorders, Drugs, Depression, Psychiatry, Antidepressants, Bipolar disorder, Major depressive disorder, Esketamine

KIELPIN, Poland, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Celon Pharma($CLN.PL) today announced positive top-line results from a Phase II study of Falkieri (proprietary esketamine dry powder inhalation) in acute phase of treatment-resistant bipolar depression.

Key Points: 
  • KIELPIN, Poland, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Celon Pharma($CLN.PL) today announced positive top-line results from a Phase II study of Falkieri (proprietary esketamine dry powder inhalation) in acute phase of treatment-resistant bipolar depression.
  • This was a randomized, double-blind, placebo-controlled, multi-center study of 88 adult patients with an inadequate response to at least two evidence-based treatment lines in bipolar depression.
  • We are extremely pleased with the robustness of the data from our Phase 2 trial, demonstrating that Falkieri shows real promise for patients with treatment-resistant bipolar depression, a highly debilitating condition with very few effective and approved therapeutic options.
  • This is highly important because majority of people with bipolar depression exhibit chronic and refractory course saidMaciej Wieczorek, PhD, Celon Pharma's CEO and Head of Research & Development.